Summary
An increase in platelet monoamine oxidase (MAO) B activity in drug-free parkinsonians (n=6) compared with healthy controls (n=10) has been confirmed using both phenylethylamine (PEA) and dopamine as substrates, reaching statistical, significance in the case of PEA oxidising activity (p<0.05). Thus, certain reports of raised platelet MAO B activity towards PEA but decreased activity towards dopamine in parkinsonians, raising the possibility of the existence of an abnormal form of MAO B in this condition, cannot be supported.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Danielczyk W, Streifler M, Konradi C, Riederer P, Moll G (1988) Platelet MAO-B activity and the psychopathology of Parkinson's disease, senile dementia and multiinfarct dementia. Acta Psychiatr Scand 78: 730–736
Davis CG, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM, Kopin IJ (1979) Chronic parkinsonism secondary to intravenous administration of meperidine analogues. Psychiatry Res 1: 249–254
Glover V, Sandler M, Owen F, Riley GJ (1977) Dopamine is a monoamine oxidase B substrate in man. Nature 265: 80–81
Glover V, Lees AJ, Ward C, Stern GM, Sandler M (1983) Platelet phenolsulphotransferase activity in Parkinson's disease. J Neural Transm, 57: 95–102
Humfrey CDN, Steventon GB, Sturman SG, Waring RH, Griffiths B, Williams AC (1990) Monoamine oxidase substrates in Parkinson's disease. Biochem Pharmacol 40: 2562–2564
Kuiper MA, Konings CH, Bergmans PLM, Wolters EC (1991) Monoamine-oxidase-B activity in untreated and treated Parkinsonian patients. 10th International Symposium on Parkinson's Disease, Tokyo, p. 182 (Abstract)
Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979–980
Langston JW, Irwin I, Langston EB, Forno LS (1984) Pargyline prevents MPTP-induced parkinsonism in primates. Science 225: 1480–1482
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265–267
Mann JJ, Stanley M, Kaplan RD, Sweeney J, Neophytides A (1983) Central catecholamine metabolism in vivo and the cognitive and motor deficits in Parkinson's disease. J Neurol Neurosurg Psychiatry 46: 905–910
Sneddon JM (1973) Blood platelets as a model for monoamine-containing neurones. Prog Neurobiol 1: 151–198
Stahl SM (1985) Platelets as pharmacological models for the receptors and biochemistry of monoaminergic neurons. In: Longenecker G (ed) The platelets: physiology and pharmacology. Academic Press, New York, pp 307–340
Steventon GB, Sturman SG, Heafield MTE, Waring RH, Napier J, Williams AC (1989) Platelet monoamine oxidase B activity in Parkinson's disease J Neural Transm (PD Sect) 1: 255–261
Steventon GB, Sturman SG, Heafield MTE, Waring RH, Napier J, Williams AC (1990) Platelet monoamine oxidase B and Parkinson's disease. Lancet i: 180
Summers KM, Brown GK, Craig IW, Littlewood J, Peatfield R, Glover V, Rose FC, Sandler M (1982) Platelet monoamine oxidase: specific activity and turnover number in headache. Clin Chim Acta 121: 139–146
Zeller EA, Boshes B, Arbit J, Bieber M, Blonsky ER, Dorkart M, Huprikar SV (1976) Molecular biology of neurological and psychiatric disorders. I. Effect of parkinsonism, age, sex and L-dopa on platelet monoamine oxidase. J Neural Transm 39: 63–77
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jarman, J., Glover, V., Sandler, M. et al. Platelet monoamine oxidase B activity in Parkinson's disease: A re-evaluation. J Neural Transm Gen Sect 5, 1–4 (1993). https://doi.org/10.1007/BF02260909
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02260909